ADCs in Breast Cancer: Sequencing, Resistance, and Managing Toxicity

ADCs in Breast Cancer: Sequencing, Resistance...

Up next

Highlights From the 2026 ASCO GI Cancers Symposium

Dr. Monty Pal and Dr. Mary Feng discuss the latest advances in metastatic colorectal, gastric, and gastroesophageal cancers that were presented at the 2026 ASCO Gastrointestinal Cancers Symposium. 

Expanding Treatment Options for Breast Cancer: ADCs and Oral SERDs

Dr. Monty Pal and Dr. Hope Rugo discuss advances in antibody-drug conjugates for various breast cancer types as well as treatment strategies in the new era of oral SERDs for HR-positive breast cancer. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I' ...  Show more

Recommended Episodes

Endocrine and Targeted Therapy for HR-Positive, HER2-Negative Metastatic Breast Cancer – Capivasertib-Fulvestrant: Rapid Guideline Update
ASCO Guidelines

Dr. Angela DeMichele, Dr. Lynn Henry, and Dr. Harold Burstein present the latest breast cancer rapid recommendation update impacting two ASCO guidelines. This update focuses on the new option, capivasertib plus fulvestrant, for patients with hormone receptor-positive, HER2-negati ...  Show more

HER2 Testing in Breast Cancer: ASCO-CAP Guideline Update
ASCO Guidelines

Dr. Antonio Wolff and Dr. Kim Allison discuss the latest ASCO-CAP guideline update on HER2 testing in breast cancer. This guideline update affirms previous recommendations, and provides commentary based on data from the DESTINY-Breast04 trial. Dr. Wolff and Dr. Allison review the ...  Show more

Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer – CDK4/6 Inhibitors Rapid Update
ASCO Guidelines

Dr. Rachel Freedman and Dr. Sharon Giordano share the latest rapid guideline update from ASCO on the adjuvant use of the CDK4/6 inhibitors abemaciclib and ribociclib in patients with stage II and III breast cancer. They share details on the impetus for the update, supporting evid ...  Show more

Systemic Therapy for Advanced HER2-Positive Breast Cancer Guideline Update
ASCO Guidelines

An interview with Dr. Sharon Giordano from the University of Texas MD Anderson Cancer Center in Houston, TX, and Dr. Nancy Davidson from Fred Hutchinson Cancer Research Center and the University of Washington in Seattle, WA, co-chairs on "Systemic Therapy for Advanced HER2-Positi ...  Show more